Journal: Urology
Article Title: Impact of Number of Cycles of Collagenase Clostridium Histolyticum on Outcomes in Patients with Peyronie's Disease.
PMID/MRN: 27816605
Publication Date: 2016-Nov-02
Abstract:
To analyze the impact of the number of cycles of collagenase Clostridium histolyticum (CCH) intralesional injection therapy on outcomes to further characterize CCH therapy.
We conducted a retrospective review of the records of all patients treated with CCH for Peyronie disease between April 2014 and March 2016. Collected variables included demographics, pre- and posttreatment sexual function, penile curvature, penile vascular findings, and treatment outcomes.
A total of 77 patients were included in the study, of which 41 (53%) completed 4 cycles of treatment, consisting of 8 total injections. For all-comers regardless of numbers of cycles, curvature improved from 58.2¡ (standard deviation = 17.9¡, range = 30¡-105¡) pre-treatment to 41.0¡ (standard deviation = 17.0¡, range = 0¡-85¡) posttreatment (P < .001). In a repeated measures model, penile curvature improved significantly following the first 3 cycles, but not the fourth. Patients who had a ³20% final reduction in curvature had a significantly greater change in curvature following the first injection (-16.2¡ vs -5.8¡, P < .001).
Intralesional CCH therapy is an effective minimally invasive treatment for Peyronie disease, although the therapeutic benefit may decline after the third cycle of treatment. Patients with ³20% reduction in curvature at the conclusion of treatment documented a greater curvature improvement after the first cycle and received more cycles of CCH.
Copyright å© 2016 Elsevier Inc. All rights reserved.